Form EFFECT Karyopharm Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
RBC Capital Reiterates Outperform Rating on Karyopharm Therapeutics (KPTI)
June 10, 2024 5:39 AM EDTRBC Capital analyst Brian Abrahams reiterated an Outperform rating and $3.00 price target on Karyopharm Therapeutics (NASDAQ: KPTI)
The analyst comments "Reflecting on ASCO and digesting the latest selinexor updates, we believe the longer follow-up data in TP53wt EC, KOL perspectives... More
